Skip to main content

Advertisement

SpringerLink
Log in

EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

An Erratum to this article was published on 27 June 2007

Abstract

Introduction

32P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom 32P is the most optimal treatment option, an assertion supported by two large studies with long follow-up.

Purpose

The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for 32P phosphate therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Najean Y, Rain JD for the French Polycythemia Study Group. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997;89(7):2319–27.

    CAS  PubMed  Google Scholar 

  2. Brandt L, Anderson H. Survival and risk of leukaemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus. Eur J Haematol 1995;54(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  3. Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004;41 (2 suppl 3):18–22.

    Article  CAS  PubMed  Google Scholar 

  4. Barbui T. The leukaemia controversy in myeloprolifertive disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41 (2 Suppl 3):15–7.

    Article  PubMed  Google Scholar 

  5. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide Study Group. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leukemia Res 2005;29:481–91.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Lund University Hospital, 221 85, Lund, Sweden

    Jan Tennvall

  2. Department of Nuclear Medicine, University Medical Centre, Maastricht, The Netherlands

    Boudewijn Brans

Authors
  1. Jan Tennvall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Boudewijn Brans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Tennvall.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00259-007-0484-4

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tennvall, J., Brans, B. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. Eur J Nucl Med Mol Imaging 34, 1324–1327 (2007). https://doi.org/10.1007/s00259-007-0407-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0407-4

Keywords

Search

Navigation